top of page
unnamed.png

ニュース

 

  • ​

掲載年

 

  • カテゴリー

 

  • 全てを見る

 

2020年7月16日

ニュースリリース

SCSKとコンテナセキュリティ領域におけるビジネスに関する業務推進を開始

ニュースリリース

「在宅/デジタルシフト」を実現する新基盤『ONE CONTACT Network』とロケーションフリーを実現するニューノーマルなセンター運営の提供開始について

2020年7月15日

ニュースリリース

「現場に任せて安心」の共同型RPA・AI-OCRによりスマート自治体の実現に貢献

ニュースリリース

統合ID管理ソリューションの最新版「VANADIS Identity Manager Ver.6.6.2.9.0」を提供開始（

2020年7月14日

ニュースリリース

投資信託運用レポート等のDX支援について（

2020年7月13日

ニュースリリース

NTTデータのデジタル技術が全英オープンゴルフ史上初のバーチャルトーナメントを支援

ニュースリリース

“お客様のミッション解決”法人向けに特化したxRソリューション）

2020年7月10日

ニュースリリース

金融業界向け自然言語処理技術の検証開始

2020年7月9日

ニュースリリース

intra-martクラウドサービスAccel-Martを活用し押印業務を大幅削減！「テレワーク応援キャンペーン」を開始（

2020年7月3日

ニュースリリース

AnserParaSOL®で利用者数に応じた新料金プランを提供開始

ニュースリリース

新規事業の実態調査レポート（株式会社クニエ）

2020年7月1日

ニュースリリース

株式会社武蔵野銀行に対する「遺言代用信託（解約制限・みまもり機能付）」管理システム提供開始について（株式会社エックスネット）

ニュースリリース

北日本銀行にて「ABIC ASSET CLOUD」採用

2020年6月30日

ニュースリリース

「AI開発プロセス」を体系的に整理し、AI案件への試行適用を開始

サービスインフォメーション

3Dプリンタを活用したAMソリューション新会社を設立

ニュースリリース

クラウドへのアカウント連携ソフトウエア「VANADIS® Cloud Connector」を提供開始（NTTデータ先端技術株式会社）

ニュースリリース

スマート農業技術を活用した落花生生産の機械化実証事業の開始

2020年6月26日

お知らせ

サイバーセキュリティに関するグローバル動向四半期レポート（2020年1月～3月）を公開

2020年6月25日

ニュースリリース

電気事業者向けクラウドサービス｢ECONO-CREA®｣にサブスクリプション機能を追加

ニュースリリース

クレジットカード会社向け不正対策サービス「CAFIS Transaction Manager™」提供開始

ニュースリリース

「intra-mart Award 2020」受賞パートナー企業を発表

2020年6月24日

ニュースリリース

「グリッドスカイウェイ有限責任事業組合」の事業拡大について

2020年6月23日

お知らせ

Everest Groupの「Open Banking IT Services PEAK Matrix® Assessment 2020」においてオープンバンキング分野がリーダーポジション評価を獲得

お知らせ

NelsonHall社のUX-UIサービスに関するレポートにおいてリーダー評価を獲得

2020年6月19日

ニュースリリース

​

2020年6月より、小学生向けIT教育の新ブランド「データアカデミア」をスタート

news


​

Publication year

 

Category

 

View all

 

July 16, 2020

news release

Start of business promotion related to business in SCSK and container security area

news release

New platform "ONE CONTACT Network" to realize "at home/digital shift" and new normal center operation to realize location free

July 15, 2020

news release

Contributing to the realization of smart local governments through collaborative RPA/AI-OCR that "trusts the site and is safe"

news release

The latest version of the integrated ID management solution, "VANADIS Identity Manager Ver.6.6.2.9.0", is now available (

July 14, 2020

news release

DX support such as investment trust management reports (

July 13, 2020

news release

NTT DATA's digital technology supports the first virtual tournament in British Open Golf history

news release

"Customer mission solution" xR solution specialized for corporations)

July 10, 2020

news release

Started verification of natural language processing technology for the financial industry

July 9, 2020

news release

Significantly reduce stamping work by utilizing intra-mart cloud service Accel-Mart! "Telework support campaign" started (

July 3, 2020

news release

Anser ParaSOL® launches new price plan according to the number of users

news release

Fact-finding report of new business (Kunie Co., Ltd.)

July 1, 2020

news release

Commencement of provision of management system for "will-in-place substitute trust (with cancellation restrictions and Mimamori function)" to Musashino Bank, Ltd. (X-net Co., Ltd.)

news release

Adopted "ABIC ASSET CLOUD" at the Kita Nihon Bank

June 30, 2020

news release

Systematically organize "AI development process" and start trial application to AI projects

Service information

Established new AM solution company utilizing 3D printers

news release

Launched "VANADIS® Cloud Connector", software for linking accounts to the cloud (NTT DATA Advanced Technology Co., Ltd.)

news release

Commencement of peanut production mechanization demonstration project utilizing smart agricultural technology

June 26, 2020

Notice

Release of Global Trend Quarterly Report on Cyber ​​Security (January to March 2020)

June 25, 2020

news release

Addition of subscription function to "ECONO-CREA®" cloud service for electric utilities

news release

Launch of "CAFIS Transaction Manager™", a fraud prevention service for credit card companies

news release

Announced "intra-mart Award 2020" winning partner companies

June 24, 2020

news release

Business expansion of "Grid Skyway Limited Liability Partnership"

June 23, 2020

Notice

Everest Group's Open Banking IT Services PEAK Matrix® Assessment 2020 wins leader position in open banking

Notice

Nelson Hall's UX-UI Services Report Receives Leader Rating

June 19, 2020

news release

​​

Starting a new IT education brand "Data Academia" for elementary school students from June 2020

​

新闻




出版年份



类别



查看全部



2020年7月16日

新闻发布

开始在SCSK和集装箱安全区域开展与业务有关的业务推广

新闻发布

推出新平台“ ONE CONTACT Network”以实现“在家/数字转换”和新的正常中心操作以实现无位置

2020年7月15日

新闻发布

通过RPA / AI-OCR合作“实现现场信任并安全”，为实现明智的地方政府做出贡献

新闻发布

集成ID管理解决方案的最新版本“ VANADIS Identity Manager版本6.6.2.9.0”现已发布（

2020年7月14日

新闻发布

DX支持，例如投资信托管理报告（

2020年7月13日

新闻发布

NTT DATA的数字技术支持英国高尔夫公开赛历史上的首次虚拟赛事

新闻发布

公司专用的“客户任务解决方案” xR解决方案）

2020年7月10日

新闻发布

开始验证金融业的自然语言处理技术

2020年7月9日

新闻发布

利用intra-mart云服务Accel-Mart大大减少冲压工作！开始了“电信支持运动”（

2020年7月3日

新闻发布

AnserParaSOL®根据用户数量启动新的价格计划

新闻发布

新业务的实况调查报告（K江株式会社）

2020年7月1日

新闻发布

开始向武藏野银行有限公司（X-net Co.，Ltd.）提供替代信托（具有取消限制和森守功能）的测试测试管理系统

新闻发布

北日本银行采用“ ABIC ASSET CLOUD”

2020年6月30日

新闻发布

系统地组织“ AI开发过程”并开始对AI项目进行试用

服务信息

利用3D打印机成立新的AM解决方案公司

新闻发布

推出用于将帐户链接到云的软件“VANADIS®Cloud Connector”（NTT DATA Advanced Technology Co.，Ltd.）

新闻发布

利用智能农业技术的花生生产机械化示范项目的启动

2020年6月26日

注意

发布关于网络安全的全球趋势季度报告（2020年1月至2020年3月）

2020年6月25日

新闻发布

为电力公司的“ECONO-CREA®”云服务增加了订阅功能

新闻发布

推出针对信用卡公司的欺诈预防服务“ CAFIS Transaction Manager™”

新闻发布

宣布“ intra-mart Award 2020”获奖合作伙伴公司

2020年6月24日

新闻发布

“ Grid Skyway有限责任合伙企业”的业务扩展

2020年6月23日

注意

Everest Group的开放银行IT服务PEAKMatrix®2020评估在开放银行中赢得领先地位

注意

Nelson Hall的UX-UI服务报告获得领导者评级

2020年6月19日

新闻发布



从2020年6月开始为小学生开设一个新的IT教育品牌“ Data Academia”

 

​

02.-チャットボットとは？今更聞けない人のために超解説！.jpg
01.-AIチャットボットのすべて！導入前に知るべき6つのポイント.jpg
06.-チャットボットが新型コロナウイルス対策で業務負担を軽減.jpg
mv_government.jpg
pic_list (3).jpg
mv_agriculture.jpg
mv_education.jpg
20180708022948-1-840x420.jpg
MzY2MTYxNg.jpeg
unnamed (1).jpg
68747470733a2f2f686162726173746f72616765
unnamed (1).jpg

Welcome to the entrance to the world of acupuncture
Acupuncturist: a profession that will not disappear in the AI ​​era
With the development of AI (artificial intelligence), many existing occupations are expected to disappear. It is said that artificial intelligence has gradually entered the high-level intellectual professional fields such as finance and legal affairs, and has begun to serve people.

But what about acupuncture?

Acupuncture is a delicate and special technique that cannot be easily replaced by computers or machines. It can only be done manually. We often hear about their physical conditions from patients, consider the cause of the current symptoms, and select appropriate treatment points from 361 acupoints (acupoints) for acupuncture. This is a complex and delicate technique. It is impossible for robots. Even if it is possible, it will not be controlled by practitioners.

On the contrary, since it is surrounded by digital devices every day, do you think it needs the warmth, softness and safety of human hands? Acupuncture is a technology that is expected to become more valuable in the future AI era.

The WHO (World Health Organization) has also certified the therapeutic effects of acupuncture. Acupuncture therapy is good at treating symptoms that are difficult to improve by Western medicine, pain that has not been diagnosed as "discomfort" (discomfort) according to the examination results, and pain that cannot be completely cured. It is understandable that in recent years, the upsurge of Oriental medicine is coming, and it is said that this is a very stressful society. There is a growing demand for acupuncturists who can understand and treat patients' pain.

In addition, acupuncturists are long-term participants of men and women. This is not hard work, so even after aging, you can use the skills and intuition accumulated according to your physical strength to stand in the field of treatment. This is a lifelong job, you can improve your skills while you work, and cultivate opportunities for success while reaping rewards.
 

ACCELERATE OUTCOMES WITH A BACKBONE FOR ARTIFICIAL INTELLIGENCE.

makes machine learning operational by connecting models to the real-world decisions they inform. Often, AI/ML algorithms live in experimental vacuums. Foundry provides the end-to-end infrastructure an organization needs to apply AI/ML to real problems and real data:

  • A data foundation.  provides the data engineering capabilities an organization needs to deploy AI/ML models it can trust. Organizations use  to build a solid foundation of sufficient, quality data, then bring that data into daily operations.

  • Production deployment infrastructure. revolutionizes the way organizations build and deploy AI/ML by combining a data foundation with end-to-end algorithm deployment infrastructure. Data scientists and engineers can customize, deploy, assess, and compare across homegrown, open-source, and third-party algorithms. All models are tightly integrated with end-to-end platform capabilities, ranging from feature curation and health checks to model management to inference/serving to outcome monitoring.

  • Faster feedback loops. AI/ML models rarely work on a "set it and forget it" basis.  integrates the full model lifecycle with end user actions and feedback, and with operational decisions and outcomes. This enables operationally oriented model monitoring, management, understanding, selection, and adjustment. The result is more adaptable and ambitious AI/ML, faster.

UNITE THE ORGANIZATION AROUND A SHARED ENVIRONMENT FOR MACHINE LEARNING.

The most effective AI/ML encodes and supercharges an organization's unique expertise. That requires uniting an organization's data scientists, decision-makers, and everyday employees in an environment for collaborating on AI/ML-powered operations.  collaboration infrastructure drives AI/ML that brings the organization together:

  • A unifying ontology. ontology translates an organization's complex data landscape into human-readable concepts. built models reflect how an organization views the world and unite data scientists, engineers, analysts, executives, and operational end users around a common semantic layer.

  • Granular security controls. lets organizations define granular access control policies at the integration stage, then propagates those policies intelligently across the system. Organizations can promote collaboration confidently with granular data security and transparent data governance.

  • Model templates.model templates empower low-code and no-code AI/ML so even non-technical users can use AI to accelerate and enrich their workflows.

MAXIMIZE IMPACT AND MINIMIZE RISK WITH A PLATFORM DESIGNED FOR RESPONSIBLE ENGINEERING.

Our approach to AI/ML in  reflects our foundational belief in augmenting human intelligence, not replacing it. We believe AI/ML algorithms are most effective when they empower humans to ask complex questions, interpret answers, and act on results. At public and private sector organizations around the world, driven AI/ML is accelerating human decision-making by:

  • Surfacing new leads in dark web, weapons trafficking, financial fraud, and drug trafficking investigations so investigators can identify persons of interest more quickly

  • Aggregating and correlating biomedical research data to streamline drug discovery

  • Processing entity resolution suggestions so analysts can focus on making assessments rather than manually sorting and tagging data

  • Analyzing massive-scale sensor data so that engineers can make better aircraft maintenance decisions

  • Rapidly generating simulations while allowing operators to tweak scenario variables, leading to better-informed decisions optimized for different variables (e.g., safety rating and production quantity)

I see our approach to ethical machine learning as being grounded in an appreciation for both the promise and limitations of human-computer collaboration. The promise of AI is in augmenting and enhancing human intelligence, expertise and experience. Think helping a aircraft mechanic make better, more accurate and more timely repairs – not automating the mechanic out of the picture.

— Anthony Bak, Co-Lead of Palantir's Machine Learning team, in an interview with CTOVision

Protecting privacy and preserving civil liberties is fundamental to our mission.ships with technical capabilities that enable ethical engineering and ethical machine learning, including data protection features such as granular access controls, data provenance and lineage tracking, data retention and deletion management, and audit logging.  also enables industry-leading monitoring and validation for AI models. Its flexible, configurable tools let organizations evaluate model bias, in terms of both the data used to train the model and model outcomes.

We recognize that technology alone can't fully mitigate the risks of machine bias. Our dedicated Privacy and Civil Liberties team works with our engineers and our customers to approach building and deploying AI/ML thoughtfully.

Acupuncture significantly reduces AI-associated arthralgias

Publish date: December 8, 2017

By 

Roxanne Nelson

 

 

 

REPORTING FROM SABCS 2017

SAN ANTONIO – Acupuncture significantly reduced joint pain that was associated with the use of aromatase inhibitors (AIs) in women with early breast cancer, according to new findings reported at the San Antonio Breast Cancer Symposium.

The randomized, phase 3 SWOG S1200 clinical trial found that, compared with sham acupuncture and a control group receiving no therapy, women receiving acupuncture reported significantly lower scores on the Brief Pain Inventory–Short Form (BPI).

“We have shown consistently, with multiple measures assessing pain and stiffness, that true acupuncture generated better outcomes than either control group in a large multicenter trial,” said lead author Dawn L. Hershman, MD, leader of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center. “Acupuncture provides a nonpharmacologic option that can improve symptoms and possibly increase AI adherence and subsequent breast cancer outcomes.”

AIs can reduce both early breast cancer recurrence and mortality. Dr. Hershman noted that these agents are effective in the adjuvant setting and for prevention “but we know that it doesn’t work if you don’t take it. Noncompliance is a major problem among women taking hormonal therapy.”

Noncompliance is multifactorial and one of the main reasons women discontinue their therapy early is because of arthralgias or joint discomfort. “We were interested in a nonpharmacologic intervention, to assess whether or not we could control these symptoms.”

Dr. Hershman pointed out acupuncture provides a safe and effective alternative for patients reluctant to take a prescription medication that can result in other side effects. “Identification of nonopioid options for pain control is a public health priority,” she said.

Acupuncture is a popular nonpharmacologic modality and widely used for a number of indications. Several single-institution studies have suggested that it may be useful for controlling AI-associated arthralgias, while other studies have not demonstrated a benefit.

In this trial, the authors evaluated the efficacy of acupuncture, compared with sham acupuncture or waitlist control, in the treatment of AI associated arthralgia in a large population of patients. The study was conducted at 11 centers.

The cohort comprised 226 postmenopausal women diagnosed with early-stage, hormone receptor–positive breast cancer who were receiving treatment with AIs. The primary endpoint was the decline in joint pain as measured by BPI-SF at 6 weeks, and to assess the duration of the effect, the women were followed for an additional 12 weeks.

Within this group, 110 were randomized to true acupuncture; 59 to sham acupuncture, and 57 to waitlist control (no treatment). Patients receiving true or sham acupuncture had sessions three times a week for 6 weeks followed by one session per week for 6 more weeks. Pain status was reported at baseline, during treatment, and then afterwards, using a variety of measurement tools including the BPI-SF, which is a self-administered 14-item questionnaire that evaluates pain severity on a 0-10 scale, and the impact of pain on activities of daily living.

At 6 weeks, the true acupuncture treatment arm reported significantly lower BPI worst pain scores than those in the sham acupuncture and the waitlist control arms. The mean BPI worst pain for the true acupuncture arm was 0.92 points lower than the sham acupuncture arm (P = .01) and 0.96 points lower than the waitlist control arm (P = .01). The proportion of patients experiencing a large reduction in BPI worst pain (greater than 2) was significantly greater in the true acupuncture arm, compared with the other groups: 58% versus 33% percent and 31%, respectively. The differences continued to remain statistically significant at 24 weeks, even though the treatment only continued for 12 weeks.

Associated adverse effects were minimal with true and sham acupuncture and limited to grade 1 bruising.

The cost of the 12-week intervention was about $1,250 or $65-$75 a session. “We feel that there is now sufficient evidence to support insurance coverage of acupuncture of AI arthralgia.”

In a discussion of the paper, Dr. Anne Partridge, from the Dana Farber Cancer Center, noted that it is imperative to seek new ways to improve outcomes in breast cancer, and AIs are contributing to that. However, she echoed the concern that nonadherence to treatment is a “tremendous problem” and hampers the clinical effectiveness of AI therapy.

The rate of discontinuation during the first year of therapy is 20% within the first year and up to 40% of patients do not take them daily. Both early discontinuation and nonadherence contribute to mortality.

Based on these results from the largest randomized controlled trial looking at acupuncture in this setting, should physicians be recommending acupuncture to patients prescribed AI therapy?

“The short answer is, why not?” said Dr. Partridge, “And that we should be recommending it for some of our patients.”

However, there are a number of issues that need to be addressed, she added. The duration of treatment is not known, and the need for follow-up treatment or the frequency of it is not known. The generalizability of it is also unclear when looking at a larger population, and acupuncture is highly operator dependent.

“There are cost and access issues, and insurance right now offers very limited coverage,” she said.

Importantly, Dr. Partridge emphasized, “We know that it will help symptoms, but will it improve adherence to AI?”

It may improve adherence for some patients, but “side effects are only one factor,” she said. “Adherence behavior is complicated. We need to figure out how to optimize these therapies in our patients.”

This study was supported by the National Institutes of Health National Center for Complementary and Integrative Health and the Office of Research on Women’s Health, and grants from the NIH/National Cancer Institute Division of Cancer Prevention. Dr. Hershman declared no conflicts of interest. Dr. Partridge had no disclosures.

empty-wheelchair-parked-in-hospital-pict
digitwin.png

Illumina, Chinese Children's Hospital to Launch Newborn Sequencing Study

Apr 23, 2019

 

| 

staff reporter

 

NEW YORK (GenomeWeb) – Illumina and the Children's Hospital of Fudan University in China plan to launch a study of whole-genome sequencing in the hospital's neonatal intensive care unit to determine whether it can be used as a diagnostic for critically ill infants, Illumina said this week.

According to Illumina, the researchers plan to enroll 200 patients and compare the diagnostic rate of rapid WGS with genetic diagnostic methods such as microarray analysis and gene panel sequencing.

The researchers will also compare the time it takes to reach a diagnosis, impact on the patient's prognosis, and turnaround time.

Illumina will provide the sequencing reagents and the Children's Hospital of Fudan University will conduct the testing and data analysis and also be responsible for reporting results and providing genetic consultations with family members.

The hospital is also a sponsor of the Newborn Genome Project, which is creating a genome database for newborns in China in order to develop better methods for detecting genetic diseases in newborns and to establish standards for neonatal genetic diseases.

UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

Dec 13, 2019

 

| 

staff reporter

 

NEW YORK – Researchers from the Institute of Cancer Research, London and the Royal Marsden NHS Foundation Trust have presented data demonstrating that blood-based genotyping assays can accurately detect specific biomarkers and potentially be used to guide targeted treatment of metastatic breast cancer. 

The researchers used Guardant Health's liquid biopsy assay and Bio-Rad Technologies' droplet digital PCR (ddPCR) testing to identify errors — including mutations in the HER2, ESR1 and AKT1 genes — in circulating tumor DNA (ctDNA) that had been shed into the patients' bloodstream. 

During a presentation this week at the San Antonio Breast Cancer Symposium (SABCS), Nicholas Turner, molecular oncology professor at the Institute of Cancer Research, explained that his team wanted to solve the issue of genotyping breast cancer tumors without having to perform multiple biopsies. Turner highlighted the need for prospective studies to assess the accuracy of ctDNA testing in routine practice and the potential of these tools to guide targeted therapy without requiring solid tissue testing. 

With funding from Stand Up To Cancer (a fundraising campaign from Cancer Research UK and Channel 4) Turner's team therefore launched an ongoing prospective study, called "plasmaMATCH," to examine the clinical utility of ctDNA for metastatic breast cancer detection. The group enrolled a total of 1,044 patients with advanced breast cancer who had either progressed on prior drug therapy or relapsed within a year after adjuvant chemotherapy. 

The researchers analyzed ctDNA in blood samples from patients using the Guardant360 sequencing-based assay and Bio-Rad's ddPCR as an orthogonal method. Patients with identified mutations could also enroll in a treatment arm of the study that matched their mutation. 

Turner and his team split the patient population into three major cohorts depending on specific genetic errors found in ctDNA: ESR1 mutations, HER2 mutations, and AKT-1 mutations in estrogen-receptor-positive breast cancer. The researchers also added a fourth cohort that had AKT-1 and PTEN mutations based on both ctDNA and tumor sequencing results, as well as a fifth group with triple-negative breast cancer without mutations. 

While Turner's team's initially aimed to measure the response rate of targeted therapies matched to mutations in ctDNA without tissue testing, the researchers also monitored the frequency of mutations, accuracy of testing, proportion of patients entering a treatment cohort, and the activity in clonality-dominant versus subclonal mutations. Turner's team discovered that 784 patients who had cfDNA testing done with both Guardant360 and ddPCR had "very strong agreement" of between 96 and 99 percent. Comparing the ctDNA to the patients' tumor samples to validate the plasmaMATCH findings, the researchers found that the liquid biopsy assay had an overall sensitivity of 93 percent. 

Guardant360 also identified several more targetable alterations than hotspot testing, including over 35 percent more PIK3CA mutations that can be targeted by US Food and Drug Administration-approved therapies. The assay also detected significantly more ESR1 mutations and found previously undetected microsatellite instability and ERBB2 mutations.   

The researchers provided 142 patients that had specific identified mutations experimental targeted therapies as part of the study, and they plan to test the treatments that showed initial promise in larger clinical trials. 

The researchers now believe that they can use blood testing to identify rare subtypes of breast cancer, in addition to potentially replacing more invasive methods of breast cancer detection. 

"We have now confirmed that blood tests can quickly give us a bigger picture of the mutations [that] are present within multiple tumors throughout the study," Turner said in a statement.  

"We show that circulating tumor DNA testing offers a simple, efficient, and fast method of tumor genotyping," Turner also noted during the presentation at SABCS. "The patients with mutations identified in their ctDNA have efficacy with matching target[ed] therapies." 

The researchers believe the blood-based assays are now reliable enough to be applied routinely by clinicians after receiving regulatory approval.

"As the number of treatment-relevant genomic alterations in metastatic breast cancer continues to grow, it is critical that oncologists have a simple and reliable way to comprehensively test for this information about their patients," Guardant Health Global Chief Medical Officer Rick Lanman said in a statement. "Guardant360 detected changes in the genome picture over time … and also identifies targetable but uncommon genomic biomarkers."

1c8b9b577cc41266ebab5e65ff8f3de8.jpg
090320_COVID_Test_0111-1024x682.jpg
05b50bc878af8f403a01848035fa3a86.jpg
7d54e3018152c4d0b389e55596039404.jpg
4deac0802d4054a8a85b3f3d256911aa.jpg
hocit999 - コピー_ページ_16.jpg
hocit999_ページ_6.jpg
bottom of page